These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 5936302)

  • 1. Clinical judgment in the assessment of psychopharmacological effects.
    Paredes A; Baumgold J; Pugh LA; Ragland R
    J Nerv Ment Dis; 1966 Feb; 142(2):153-60. PubMed ID: 5936302
    [No Abstract]   [Full Text] [Related]  

  • 2. Prien RF, Cole JO: High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health--psychopharmacology research branch collaborative study group.
    Arch Gen Psychiatry; 1968 Apr; 18(4):482-95. PubMed ID: 4868797
    [No Abstract]   [Full Text] [Related]  

  • 3. Methodological issues in psychopharmacological research.
    Davis JM; Hurt SW
    Am J Orthopsychiatry; 1977 Jul; 47(3):523-36. PubMed ID: 888926
    [No Abstract]   [Full Text] [Related]  

  • 4. Methodological issues in psychopharmacological research: chlorpromazine--a case in point.
    Marholin D; Phillips D
    Am J Orthopsychiatry; 1976 Jul; 46(3):477-95. PubMed ID: 941992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships.
    Clark ML; Ray TS; Paredes A; Ragland RE; Costiloe JP; Smith CW; Wolf S
    Psychosom Med; 1967; 29(6):634-42. PubMed ID: 5582955
    [No Abstract]   [Full Text] [Related]  

  • 6. The hospitalization proneness scale as a predictor of response to phenothiazine treatment.
    Rosen B; Engelhardt DM; Freedman N; Margolis R
    J Nerv Ment Dis; 1968 Jun; 146(6):476-80. PubMed ID: 5677025
    [No Abstract]   [Full Text] [Related]  

  • 7. Prediction of psychiatric hospitalization. II. The Hospitalization Proneness Scale: a cross-validation.
    Rosen B; Engelhardt DM; Freedman N; Margolis R; Rudorfer L; Paley HM
    J Abnorm Psychol; 1972 Dec; 80(3):271-4. PubMed ID: 4639912
    [No Abstract]   [Full Text] [Related]  

  • 8. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia.
    Morton MR
    Am J Psychiatry; 1968 May; 124(11):1585-8. PubMed ID: 4869439
    [No Abstract]   [Full Text] [Related]  

  • 9. MULTIPLE ITEM FACTORS AS CHANGE MEASURES IN PSYCHOPHARMACOLOGY.
    KLEIN DF; FINK M
    Psychopharmacologia; 1963 Feb; 4():43-52. PubMed ID: 14050411
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of butaperazine in chronic schizophrenia.
    Clark ML; Ray TS; Huber WK; Willis D; Ramsey HR
    Clin Pharmacol Ther; 1968; 9(6):757-64. PubMed ID: 4387043
    [No Abstract]   [Full Text] [Related]  

  • 11. QUANTIFICATION OF PSYCHIATRIC MENTAL STATUS. FOR USE WITH PSYCHOTIC PATIENTS.
    ROCKLAND LH; POLLIN W
    Arch Gen Psychiatry; 1965 Jan; 12():23-8. PubMed ID: 14221688
    [No Abstract]   [Full Text] [Related]  

  • 12. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients.
    Hekimian LJ; Friedhoff AJ
    Dis Nerv Syst; 1967 Oct; 28(10):675-8. PubMed ID: 4860896
    [No Abstract]   [Full Text] [Related]  

  • 13. Statistical strategies for prediction of clinical response: performance tests as predictors of reduction in psychopathology.
    Schooler NR; Collins PJ; Sakalis G
    Psychopharmacol Bull; 1978 Oct; 14(4):86-8. PubMed ID: 704772
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients.
    Greenberg LM; Roth S
    Am J Psychiatry; 1966 Aug; 123(2):221-6. PubMed ID: 5947494
    [No Abstract]   [Full Text] [Related]  

  • 15. SYKES TF: EXTRAPYRAMIDAL SIDE EFFECTS AND THERAPEUTIC RESPONSE.
    BISHOP MP; GALLANT DM
    Arch Gen Psychiatry; 1965 Aug; 13():155-62. PubMed ID: 14314761
    [No Abstract]   [Full Text] [Related]  

  • 16. A fortran program for computation of results of controlled studies in therapeutics.
    Turner WJ; Krumholz W; Merlis S
    Int J Neuropsychiatry; 1965 Oct; 1(5):481-90. PubMed ID: 5323583
    [No Abstract]   [Full Text] [Related]  

  • 17. Critical study of the Organic Integrity Test as a diagnostic and therapeutic index in schizophrenia.
    Kay SR; Gang RG
    Percept Mot Skills; 1973 Dec; 37(3):827-33. PubMed ID: 4587547
    [No Abstract]   [Full Text] [Related]  

  • 18. Schizophrenic subtypes defined by response to drugs and placebo.
    Goldberg SC; Mattsson NB
    Dis Nerv Syst; 1968 May; 29(5):Suppl:153-8. PubMed ID: 4876985
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of the behavioral effects of periodic administration of chlorpromazine and a "sustained-release" form of chlorpromazine.
    Orzack MH; Taylor CL; Kornetsky C
    Clin Pharmacol Ther; 1969; 10(2):258-64. PubMed ID: 4887298
    [No Abstract]   [Full Text] [Related]  

  • 20. Clopenthixol: a controlled trial in chronic hospitalized schizophrenic patients.
    Kordas SK; Kazamias NG; Georgas JG; Papadokostakis JG
    Br J Psychiatry; 1968 Jul; 114(512):833-6. PubMed ID: 4874163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.